News
Curated oncology headlines from reputable sources, ranked by importance with Claude Opus 5.
News about: Lung & Bronchus → cancer profile · × Clear filters
Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial
Adding ivonescimab to chemotherapy prolonged progression-free survival but NOT overall survival. In the phase 3 HARMONi trial (n=438, EGFR-mutated non-small-cell lung cancer after progression on a third-generation EGFR inhibitor), median progression-free survival was 6.8 versus 4.4 months (HR 0.52; 95% CI 0.41-0.66; p<0.0001). Median overall survival was 16.8 versus 14.0 months and did not reach s…
First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations
First-line sunvozertinib prolonged progression-free survival compared with chemotherapy, but overall survival remains unknown — the data were immature (39% maturity). In the phase 3 WU-KONG28 trial (n=324), median progression-free survival was 10.3 versus 7.5 months (HR 0.65; 95% CI 0.50-0.85; P<0.001), the objective response rate was 58.9% versus 31.1%, and median duration of response was 11.2 ve…
Mapping micrometastatic seeds of relapse
Spatial multi-omics profiling of colorectal cancer micrometastases in matched primary tumors, liver, and lung metastases revealed that liver micrometastases represent an early-evolved, stem-like, immune-suppressed residual disease state. The study identified a six-gene recurrence signature linked to these micrometastatic seeds. This finding reframes liver micrometastases as a distinct biological e…
High Rate of Surgical Success in Complex NSCLC With Neoadjuvant Chemoimmunotherapy
A small prospective study found that adding immunotherapy to neoadjuvant chemotherapy more than doubled mediastinal lymph node clearance rates in patients with stage III non-small cell lung cancer. The improved nodal response facilitated more complete surgical resections in these complex cases. These findings support the growing body of evidence that chemoimmunotherapy before surgery can downstage…
Medicaid Expansion and Stage at Diagnosis, Timely Initiation and Receipt of Guideline-Concordant Treatment, and Survival Among People With Non–Small Cell Lung Cancer
A study published in the Journal of Clinical Oncology examined the impact of Medicaid expansion on outcomes for patients with non-small cell lung cancer (NSCLC). The research assessed whether expanded insurance coverage led to earlier-stage diagnoses, more timely treatment initiation, greater adherence to guideline-concordant therapy, and improved survival. The findings contribute to the growing b…
Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced RET Fusion–Positive Non–Small Cell Lung Cancer
The Journal of Clinical Oncology has published the final efficacy and safety results from the phase I/II ARROW trial evaluating pralsetinib in patients with advanced RET fusion-positive non-small cell lung cancer. Pralsetinib is a selective RET kinase inhibitor designed for the subset of NSCLC patients harboring RET gene fusions, which occur in approximately 1-2% of cases. The final data from this…
Artificial intelligence model boosts lung nodule diagnostic accuracy in clinical trial
DeepFAN is a transformer-based model trained on more than 10,000 pathology-confirmed lung nodules and evaluated in a multireader, multicase clinical trial (Chinese Clinical Trial Registry ChiCTR2400084624; primary publication: Nature Cancer, DOI 10.1038/s43018-026-01147-w). The model reached an AUC of 0.939 (95% CI 0.930-0.948) on an internal test set and 0.954 (95% CI 0.934-0.973) on the trial da…
Improving immunotherapy in solid tumors using FMT
A paper in Cell describes faecal microbiota transplantation (FMT) as an addition to first-line immune checkpoint inhibitor therapy in renal cell carcinoma, cutaneous melanoma and non-small-cell lung cancer. The authors report improved efficacy with an acceptable safety profile and link it to remodelling of the gut microbiome and systemic immunometabolic changes. The available abstract gives neithe…